. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Parkinsonism Relat Disord. 2015 Jan 5;21(3):271–276. doi: 10.1016/j.parkreldis.2014.12.027

Table 1.

Demographics and CSF biomarker values of the discovery and validation cohorts at the start of Phase 1 in the DATATOP sample

		Discovery (n=201)	Validation (n=202)	Total (n=403)
Sex, F/M (% male)		71/130 (54.6%)	71/131(54.2%)	142/261 (54.4%)

Age (yrs)	Mean ± SD	60.94 ± 9.55	60.93 ± 8.82	60.93 ± 9.18
Age (yrs)	Range	36 – 78	34 – 79	34 – 79

Disease Duration (yrs)	Mean ± SD	1.99 ± 1.33	2.08 ± 1.38	2.04 ± 1.36
Disease Duration (yrs)	Range	0 – 6	0 – 7	0 – 7

MMSE	Mean ± SD	28.78 ± 1.48	28.97 ± 1.41	28.87 ± 1.45
MMSE	Range	23 – 30	23 – 30	23–30

UPDRS total	Mean ± SD	25.77 ± 11.10	22.91 ± 12.17	24.34± 11.72
UPDRS total	Range	7 – 61	0 – 63	0 – 63

UPDRS motor	Mean ± SD	17.15 ± 8.46	15.47 ± 9.10	16.31± 8.82
UPDRS motor	Range	3 – 50	0 – 46	0–50

Hoehn and Yahr	Median	1.5	1.5	1.5
Hoehn and Yahr	Range	1 – 3	1 – 3	1 – 3

CSF Aβ₄₂ (pg/mL)	Mean ± SD	233.98 ± 78.63	238.29 ± 71.32	236.14 ± 74.99
CSF Aβ₄₂ (pg/mL)	Range	52.14 – 670.08	74.77 – 435.72	52.14–670.08

CSF t-tau (pg/mL)	Mean ± SD	47.27 ± 25.90	46.79 ± 25.07	47.03 ± 25.45
CSF t-tau (pg/mL)	Range	13.97 – 146.91	10.72 – 213.58	10.72 – 213.58

CSF p-tau (pg/mL)	Mean ± SD	23.23 ± 11.66	23.44 ± 12.14	23.34 ± 11.89
CSF p-tau (pg/mL)	Range	4.56 – 88.02	3.99 – 93.11	3.99 – 93.11

CSF p-tau/t-tau	Mean ± SD	0.54 ± 0.21	0.54 ± 0.21	0.54 ± 0.21
CSF p-tau/t-tau	Range	0.14 – 1.06	0.14 – 1.06	0.14 – 1.06

CSF t-tau/Aβ₄₂	Mean ± SD	0.21 ± 0.11	0.21 ± 0.13	0.21 ± 0.12
CSF t-tau/Aβ₄₂	Range	0.08 – 0.71	0.09 – 1.21	0.08 – 1.21

CSF p-tau/Aβ₄₂	Mean ± SD	0.11 ± 0.06	0.11 ± 0.07	0.11 ± 0.06
CSF p-tau/Aβ₄₂	Range	0.03 – 0.42	0.02 – 0.55	0.02 – 0.55

UPDRS: Unified Parkinson Disease Rating Scale; MMSE Mini Mental State Examination; Aβ_1-42: amyloid beta peptide 1-42; CSF: cerebrospinal fluid; p-tau: phosphorylated tau; t-tau: total tau